Interferon-β-1b and Corticoids Improve Cardiac Function of Patients with Severe Chronic Parvovirus B19 Myocarditis—A Case Series

Le résumé fourni par la source

All articles of this category (opens in new window) Background: An increase in severe chronic parvovirus B19 (PVB19) myocarditis cases challenges previous guideline-recommended treatment strategies. Immunomodulation with interferon-β 1b (IFNb1b) with or without corticosteroids has been used in the past as an alternative treatment option. Here, we report a case series of four patients treated with IFNb1b and corticoids as an individual healing attempt. Methods: Four biopsy-confirmed PVB19 myocarditis patients with severe left ventricular (LV)-dilated cardiomyopathy (DCM; median age 2 years, all female) and refractory course under standard medication were treated with a combination of IFNb1b and corticoids. Prior to immunomodulatory therapy, median LV ejection fraction (LVEF) was 34% (IQR: 25.4–43.8%); median LV end-diastolic diameter (LVIDd) was 3.7 z (IQR: 0.5–5.7 z). Further, persistently high sensitive troponin I (hsTI) levels were found in three patients. Median proBNP was 14,964 ng/L (IQR: 3,997–24,686 ng/L). One patient underwent 2 weeks of treatment with venoarterial extracorporeal membrane oxygenation. All patients received at least one cycle of levosimendan, continuous or recurrent inotropic treatment with milrinone, and guideline-based medical treatment for heart failure. All received intravenous immunoglobulins. According to a recently published protocol, all four patients received IFNb1b, corticoids, and nonsteroidal anti-inflammatory drugs (NSAIDs; Esmel-Vilomera et al, 2022). We developed a checklist to collect standardized laboratory values (including hsTI, proBNP, creatinine, transaminases, and viral load) and monitored cardiac function. Results: A rapid and continuous normalization of hsTI (IQR: 1–7 days) was found in three patients, while a slower but steady decline was detected in one patient. Within a median of 14 days (IQR: 7–16 days), inotropics could finally be weaned. ProBNP declined by a median of 77.5% (IQR: 59.8–92.9%) and LVEF increased by a median of 1.3 times (IQR: 1.2–1.5) within 4 weeks, whereas LV dilatation remained stable (median LVIDd 3.7 z vs. 3.8 z). On electrocardiography, we recorded a median 1.5-fold increase in total voltage (IQR: 1.3–1.9). No serious adverse events and no PVB19 reactivation in the blood occurred. Conclusion: We conclude that immunomodulation with IFNb1b in combination with corticoids and NSAID could reduce myocardial inflammation and improve cardiac function in our cohort. This strategy may be a promising treatment option in chronic, CrP-negative, T cell-dominated PVB19 myocarditis. Publication History Article published online: 11 February 2025 © 2025. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.